Andere talen Sirnaomics Ltd.

Aandelen

2257

KYG2050P1028

Beurs gesloten - Hong Kong S.E. Andere beurzen 10:08:28 20-05-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
9,17 ^HKD	+2,46%		+23,42%	-74,39%

06:58	Sirnaomics' hoofd strategie stapt op	MT
17/05	Sirnaomics Ltd. kondigt aan dat Dr. Xiaochang Dai ontslag heeft genomen als Chief Strategy Officer	CI

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

Sirnaomics' Strategy Chief Steps Down	06:58
Sirnaomics Ltd. Announces Resignation of Dr. Xiaochang Dai as Chief Strategy Officer	17/05
Sirnaomics Ltd. Appoints Edward Yongxiang Wang as Executive Director	10/05
Sirnaomics Receives US FDA Guidance on Trials for Squamous Cell Carcinoma Treatment	17/04
Sirnaomics Ltd. Receives FDA Specific Guidance for Further Development of novel siRNA therapeutic, STP705 for Treatment of Squamous Cell Carcinoma in situ	16/04
Sirnaomics Announces 2023 Annual Results	28/03
Sirnaomics Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	27/03
Sirnaomics will Present its Innovative Dual-Targeted GalNAc muRNA Programs in 2024 OPT Conference	12/03
Sirnaomics Chairman Disposes of Shares	08/03
Sirnaomics to Present Latest Developments of STP705 for Focal Fat Reduction at IMCAS World Congress 2024	05/02
Sirnaomics Publishes Novel Mechanism of Action of RNAi Cancer Therapeutic STP707 for Solid Tumors	24/01
Basal Cell Carcinoma Pipeline, FDA Approvals, Clinical Trials Developments and Companies 2023 (Updated)	20/12
RNAimmune Receives Investigational New Drug Application Clearance from U.S. FDA for mRNA-Based Respiratory Syncytial Virus Vaccine RV-1770	18/12
Sirnaomics Gets US FDA Nod for Clinical Trial of RSV Drug	18/12
Sirnaomics Concludes First Cohort of Phase 1 Anticoagulant Drug Study	06/12
Sirnaomics Announces Successful Completion of Cohort 1 from Phase I Clinical Study of GalNAc-Based RNAi Therapeutic STP122G for Anticoagulant Treatment	05/12
Sirnaomics Ltd. Announces Successful Completion of Cohort 1 from Phase I Clinical Study of GalNAc-Based RNAi Therapeutic STP122G for Anticoagulant Treatment	05/12
Sirnaomics Promotes Francois Lebel, M.D. to Chief Medical Officer	04/12
Sirnaomics Promotes Francois Lebel, M.D. to Chief Medical Officer	01/12
Sirnaomics Ltd. Announces Executive Changes	30/11

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Sirnaomics Ltd.

Aandelen

2257

KYG2050P1028

Andere talen

Filters